

- Lee EB, Lee VM, Trojanowski JQ (2012) Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. *Nat Rev Neurosci* 13: 38-50
- Lemmens R, Moore MJ, Al-Chalabi A, Brown RH, Jr, Robberecht W (2010) RNA metabolism and the pathogenesis of motor neuron diseases. *Trends Neurosci* 33: 249-258
- Mao YS, Zhang B, Spector DL (2011) Biogenesis and function of nuclear bodies. *Trends Genet* 27: 295-306
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, *et al* (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 314: 130-133
- Okuda T, Hattori H, Takeuchi S, Shimizu J, Ueda H, Palvimo JJ, Kanazawa I, Kawano H, Nakagawa M, Okazawa H (2003) PQBP-1 transgenic mice show a late-onset motor neuron disease-like phenotype. *Hum Mol Genet* 12: 711-725
- Pellizzoni L, Yong J, Dreyfuss G (2002) Essential role for the SMN complex in the specificity of snRNP assembly. *Science* 298: 1775-1779
- Polymeridou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, *et al* (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. *Nat Neurosci* 14: 459-468
- Rabin SJ, Kim JM, Baughn M, Libby RT, Kim YJ, Fan Y, La Spada A, Stone B, Ravits J (2010) Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology. *Hum Mol Genet* 19: 313-328
- Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y, Dewey CM, Roth FP, Herz J, Peng J, *et al* (2011) Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. *J Biol Chem* 286: 1204-1215
- Shan X, Chiang PM, Price DL, Wong PC (2010) Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. *Proc Natl Acad Sci USA* 107: 16325-16330
- Talbot K, Davies KE (2008) Is good housekeeping the key to motor neuron survival? *Cell* 133: 572-574
- Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J, Hortobagyi T, Nishimura AL, Zupunski V, *et al* (2011) Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. *Nat Neurosci* 14: 452-458
- Tripsianes K, Madl T, Machyna M, Fessas D, Englbrecht C, Fischer U, Neugebauer KM, Sattler M (2011) Structural basis for dimethylarginine recognition by the Tudor domains of human SMN and SPF30 proteins. *Nat Struct Mol Biol* 18: 1414-1420
- Ule J (2008) Ribonucleoprotein complexes in neurologic diseases. *Curr Opin Neurobiol* 18: 516-523
- Veldink JH, Kalmijn S, Van der Hout AH, Lemmink HH, Groeneveld GJ, Lummen C, Scheffer H, Wokke JH, Van den Berg LH (2005) SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. *Neurology* 65: 820-825
- Veldink JH, van den Berg LH, Cobben JM, Stulp RP, De Jong JM, Vogels OJ, Baas F, Wokke JH, Scheffer H (2001) Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. *Neurology* 56: 749-752
- Wahl MC, Will CL, Luhrmann R (2009) The spliceosome: design principles of a dynamic RNP machine. *Cell* 136: 701-718
- Wan L, Battle DJ, Yong J, Gubitza AK, Kolb SJ, Wang J, Dreyfuss G (2005) The survival of motor neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal muscular atrophy. *Mol Cell Biol* 25: 5543-5551
- Wang IF, Reddy NM, Shen CK (2002) Higher order arrangement of the eukaryotic nuclear bodies. *Proc Natl Acad Sci USA* 99: 13583-13588
- Waragai M, Junn E, Kajikawa M, Takeuchi S, Kanazawa I, Shibata M, Mouradian MM, Okazawa H (2000) PQBP-1/Npw38, a nuclear protein binding to the polyglutamine tract, interacts with U5-15kD/dim1p via the carboxyl-terminal domain. *Biochem Biophys Res Commun* 273: 592-595
- Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, Lowe P, Koppers M, McKenna-Yasek D, Baron DM, *et al* (2012) Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. *Nature* 488: 499-503
- Xiao S, Sanelli T, Dib S, Sheps D, Findlater J, Bilbao J, Keith J, Zinman L, Rogaeva E, Robertson J (2011) RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. *Mol Cell Neurosci* 47: 167-180
- Yamazaki T, Chen S, Yu Y, Yan B, Haertlein TC, Carrasco MA, Tapia JC, Zhai B, Das R, Lalancette-Hebert M, *et al* (2012) FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. *Cell Rep* 2: 799-806
- Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, Kasim M, Dreyfuss G (2008) SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. *Cell* 133: 585-600

## RESEARCH PAPER

## Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients

Ryoichi Nakamura,<sup>1</sup> Naoki Atsuta,<sup>1</sup> Hazuki Watanabe,<sup>1</sup> Akihiro Hirakawa,<sup>2</sup> Hirohisa Watanabe,<sup>1</sup> Mizuki Ito,<sup>1</sup> Jo Senda,<sup>1</sup> Masahisa Katsuno,<sup>1</sup> Fumiaki Tanaka,<sup>3</sup> Yuishin Izumi,<sup>4</sup> Mitsuya Morita,<sup>5</sup> Kotaro Ogaki,<sup>6</sup> Akira Taniguchi,<sup>7</sup> Ikuko Aiba,<sup>8</sup> Koichi Mizoguchi,<sup>9</sup> Koichi Okamoto,<sup>10</sup> Kazuko Hasegawa,<sup>11</sup> Masashi Aoki,<sup>12</sup> Akihiro Kawata,<sup>13</sup> Koji Abe,<sup>14</sup> Masaya Oda,<sup>15</sup> Masaaki Konagaya,<sup>16</sup> Takashi Imai,<sup>17</sup> Masanori Nakagawa,<sup>18</sup> Shoji Tsuji,<sup>19</sup> Ryuji Kaji,<sup>4</sup> Imaharu Nakano,<sup>5</sup> Gen Sobue<sup>1</sup>

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2013-306020>).

For numbered affiliations see end of article.

**Correspondence to**

Professor Gen Sobue, Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550 Japan; [sobueg@med.nagoya-u.ac.jp](mailto:sobueg@med.nagoya-u.ac.jp)

RN and NA contributed equally.

Received 3 June 2013  
Revised 17 July 2013  
Accepted 18 July 2013  
Published Online First 9 August 2013

**ABSTRACT**

**Objective** To clarify the emergence of muscle weakness in regions of the body that affect survival, and deterioration in activities of daily living (ADL) in amyotrophic lateral sclerosis (ALS) patients.

**Methods** We conducted a multicentre-based prospective cohort study of patients with ALS. We enrolled 401 sporadic patients with ALS. Death or the introduction of invasive ventilation was defined as the primary endpoint, and the time to five clinical markers of ADL deterioration associated with bulbar paralysis or limb weakness were defined as ADL milestones. Muscle weakness was assessed in the neck flexor muscles; the bilateral abductors of the shoulders; the bilateral wrist extensor muscles; the bilateral flexor muscles of the hips; and the bilateral ankle dorsiflexion muscles. We performed Cox proportional hazards regression analyses for the primary endpoint and the five ADL milestones, adjusting for known covariate prognostic factors for ALS.

**Results** The Medical Research Council (MRC) score for the neck flexors was the most significant prognostic factor for the primary endpoint (HR 0.74,  $p < 0.001$ ), *loss of speech* (HR 0.66,  $p < 0.001$ ), and *loss of swallowing function* (HR 0.73,  $p < 0.001$ ), and was one of the significant prognostic factors for *loss of upper limb function*, *difficulty turning in bed*, and *loss of walking ability* ( $p = 0.001$ ,  $0.002$ , and  $0.008$ , respectively). The MRC score for the neck flexors was also a significant prognostic factor for covariates of the previously reported prognostic factors.

**Conclusions** Neck weakness is an independent prognostic factor for survival and deterioration in ADL in Patients with ALS.

**INTRODUCTION**

Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterised by progressive upper and lower motor neuron loss, which leads to limb and bulbar paralysis and respiratory failure.<sup>1</sup> Symptoms develop at a progressive rate, and the median survival time from disease onset is 2–4 years.<sup>2–4</sup> However, patients with ALS show extensive variability in clinical courses, with durations ranging from a few months to more than 10 years. Furthermore, major symptoms that differentially affect activities of daily living (ADL) and

prognosis also show variability among patients with different disease forms.<sup>5</sup> A better understanding of the factors influencing deterioration in ADL and prognosis would help physicians and patients determine whether and when to introduce non-invasive positive pressure ventilation, tube feeding, tracheostomy and artificial ventilation, and would lead to effective stratification strategies in clinical trials. Several studies have shown that age,<sup>6–10</sup> bulbar symptom onset,<sup>6, 7</sup> respiratory function,<sup>3, 8, 11, 12</sup> time from symptom onset to diagnosis,<sup>2, 6, 10, 13, 14</sup> functional score<sup>2, 14</sup> and rate of disease progression<sup>2, 15–17</sup> are predictors of survival. Muscle weakness in particular regions of the body affect the prognosis of ALS, although it has not been sufficiently determined which regions are most predictive.<sup>18</sup> To investigate the longitudinal course of patients with ALS and clarify the emergence of muscle weakness, which affects deterioration in ADL and ALS prognosis, we conducted a prospective, multicentre study.

**METHODS****Patient registry and follow-up system**

We constructed a multicentre registration and follow-up system called the Japanese Consortium for Amyotrophic Lateral Sclerosis research (JaCALS), which consists of 21 neurology facilities in Japan. Patients with ALS diagnosed in these facilities were consecutively registered with written informed consent. The ethics committees of all the participating institutions approved the study. Full clinical examinations were conducted at registration by neurologists in each of the respective institutions. Muscle strength was manually tested and scored with the scale of the Medical Research Council (six points, range: 0–5)<sup>19</sup> in nine muscle groups as follows: neck flexors; bilateral abductors of shoulders as representatives of proximal upper extremity muscles; wrist extensors muscles as representatives of distal upper extremity muscles; bilateral flexors of hips as representatives of proximal lower extremity muscles; and ankle dorsiflexion muscles as representatives of distal lower extremity muscles. All manual muscle testing was performed with standard positioning and procedures by certified neurologists.<sup>20</sup> The MRC score of the neck

**To cite:** Nakamura R, Atsuta N, Watanabe H, et al. *J Neurol Neurosurg Psychiatry* 2013;**84**:1365–1371.

## Neurodegeneration

flexors was determined with the patient in the supine position. We confirmed the inter-rater reliability of the manual muscle testing method employed in this study using 23 patients with neuromuscular disease. The values of the kappa statistics of each muscle ranged from 0.65 to 0.93. To standardise the procedures and the examinations, the three organising doctors (NA, RN, HaW) visited each participating facility and ascertained the evaluation methods for this study.

Disease onset was defined as when the patients became initially aware of muscle weakness or impairment of swallowing, speech, or respiration. We enrolled patients who fulfilled the revised El Escorial criteria.<sup>21</sup> The diagnostic accuracy of the enrolled patients was then assessed by members of the steering committee of the JaCALS. Included patients were then followed-up with telephone surveys conducted by clinical research coordinators (CRC) or with examinations by neurologists every 3 months, and the degree of deterioration in ADL was determined at each time point. We employed the Japanese version of the ALSFRS-R as a scale for ADL, which was validated by Ohashi *et al*, using a telephone survey system.<sup>22</sup> We confirmed the reliability of the telephone survey system for the Japanese version of the ALSFRS-R previously,<sup>23</sup> and the English version of the telephone survey system has been confirmed in several previous studies.<sup>24–26</sup> Prior to the study, we informed and trained the CRCs of the study plan, procedures for the telephone survey, ethical issues relevant to the study, and requisite considerations for patients with ALS and caregivers, and then provided them with a general knowledge of ALS.

We defined a primary endpoint and ADL milestones in the disease course of the patients with ALS and determined their occurrence by telephone survey or examinations by neurologists. The introduction of tracheostomy positive pressure ventilation (TPPV) or death of the patient was defined as the primary endpoint, and TPPV-free survival was defined as survival. *Loss of speech function*, *loss of swallowing function*, *loss of upper limb function*, *difficulty turning in bed*, and *loss of walking ability* were set as ADL milestones. The time at which each ADL milestone occurred was defined as follows: *loss of speech function* was determined to have occurred when non-vocal communication became needed; *loss of swallowing function* was determined to have occurred when parenteral or enteral feeding became needed exclusively; *loss of upper limb function* occurred when the patient needed to be fed and became unable to grip a pen; *difficulty turning in bed* occurred when the patient became unable to turn in bed alone; *loss of walking ability* occurred when the patient became unable to walk without assistance.

### Patients

A total of 520 patients with ALS were initially registered in the JaCALS from January 2006 to June 2011. We excluded 26 patients with known gene mutations: 17 patients with SOD-1 mutations, two patients with TDP-43 mutations, two patients with FUS/TLS mutations, three patients with angiogenin mutations, and two patients with C9ORF72 repeat expansions. We also excluded 13 patients with family histories of ALS and 40 patients who were categorised as clinically possible or suspected according to the revised El Escorial criteria. An additional 20 patients for whom we could not obtain follow-up information to their refusal to participate in the telephone survey were also excluded. Twenty patients were excluded due to invalid data. The study finally included 401 sporadic patients with ALS diagnosed as clinically definite, probable, or probable laboratory-supported. Of these, 382 patients were followed for more than a year or died within a year of registration, and 19 patients were

censored within a year from registration. Eleven patients declined the telephone survey during the course of the study, and we lost contact with eight patients during the survey.

### Statistical analysis

The clinical data of the registered patients were anonymised in each participating facility of the JaCALS and assigned unique patient numbers. The data were then sent to the clinical data centre located at the Nagoya University Graduate School of Medicine and inputted into the JaCALS database.

We performed Cox proportional hazards regression analyses for the time of registration to the primary endpoint or onset of each ADL milestone to evaluate the impact of muscle weakness on the time to the primary endpoint and each decline in ADL. Specifically, for the primary endpoint and each ADL, we evaluated the HR for the MRC scores in nine muscle groups (ie, neck flexors, left and right abductors of shoulders, wrist extensor muscles, flexors of hips and ankle dorsiflexion muscles) at registration, identifying the muscles groups associated with the primary endpoint and five common ADL milestones. Additionally, we examined the HR for each muscle group after adjusting for known prognostic factors as follows: age at registration,<sup>6–10</sup> gender (male vs female),<sup>6, 27</sup> disease duration,<sup>2, 6, 10, 13, 14</sup> percent vital capacity (%VC),<sup>3, 8, 11, 12</sup> ALSFRS-R score,<sup>14</sup> riluzole use (yes vs no),<sup>28</sup> bulbar symptom,<sup>6, 7</sup> and classification according to the revised El Escorial criteria (definite vs probable or probable laboratory-supported).<sup>7, 8, 10, 14</sup> We compared the time from registration to the primary endpoint or each of the previously defined ADL milestones in the patients divided by their degree of muscle weakness using the Kaplan–Meier method. The log-rank test was used to test the null hypothesis that all the Kaplan–Meier curves were equal. A two-sided  $p < 0.05$  was considered statistically significant. All statistical analyses were conducted using the PASW V18.0 program (SPSS Inc, Chicago, Illinois, USA).

## RESULTS

### Demographic characteristics of the registered patients

The patient sample comprised 244 men and 157 women. The median age at disease onset was 62.2 years (IQR: 53.5–68.5 years), and the mean follow-up period was  $2.1 \pm 1.5$  years. The follow-up rate at 1 year after registration was 95.3%. As initial symptoms, 47.4% of the patients showed upper limb weakness, 31.4% lower limb weakness, 22.9% dysarthria, 5.5% dysphagia and 2.0% cervical weakness. At registration, the median score on the ALSFRS-R was 38 (IQR: 32–42). (see online supplementary table S1).

### Identification of weakened muscle groups that affect survival and progression to the ADL milestone

Cox proportional hazard regression analyses for the primary endpoint and the ADL milestones

Table 1 shows the results of Cox proportional hazard regression analyses for the primary endpoint and the five ADL milestones, including the MRC scores of the nine muscle groups. The MRC score for the neck flexors was the most significant negative prognostic factor for the primary endpoint, *loss of speech*, and *loss of swallowing function* (HR 0.74,  $p < 0.001$ , HR 0.66,  $p < 0.001$ , HR 0.73,  $p < 0.001$ , respectively). For the *loss of upper limb function*, *difficulty turning in bed* and *loss of walking ability*, the MRC score for the neck flexors was a significant negative prognostic factor (HR 0.77,  $p = 0.001$ , HR 0.77,  $p = 0.002$ , and HR 0.80,  $p = 0.008$ , respectively). Whereas, the MRC score for the left wrist extensors was a significant positive prognostic factor for the primary endpoint and each ADL milestone except for *difficulty turning in bed*.

Table 1 Multivariate Cox regression analyses for the primary endpoint and each activity of daily living milestone using the MRC score of each muscle group at registration

Muscle group	Primary endpoint		Loss of speech		Loss of swallowing function		Loss of upper limb function		Difficulty turning in bed		Loss of walking ability	
	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
Neck flexors	0.74 (0.65 to 0.86)	<0.001	0.66 (0.56 to 0.76)	<0.001	0.73 (0.63 to 0.85)	<0.001	0.77 (0.66 to 0.89)	0.001	0.77 (0.66 to 0.91)	0.002	0.80 (0.67 to 0.94)	0.008
Left shoulder abductors	0.87 (0.69 to 1.11)	0.266	0.89 (0.69 to 1.14)	0.363	0.89 (0.71 to 1.12)	0.309	0.62 (0.49 to 0.79)	<0.001	0.72 (0.56 to 0.93)	0.012	0.75 (0.57 to 1.00)	0.049
Right shoulder abductors	0.98 (0.77 to 1.25)	0.890	1.11 (0.87 to 1.43)	0.399	1.02 (0.81 to 1.29)	0.867	1.19 (0.94 to 1.50)	0.159	1.08 (0.85 to 1.39)	0.529	0.99 (0.75 to 1.30)	0.917
Left wrist extensors	1.29 (1.04 to 1.59)	0.018	1.28 (1.03 to 1.59)	0.026	1.24 (1.02 to 1.51)	0.034	1.42 (1.14 to 1.77)	0.002	1.24 (1.00 to 1.55)	0.054	1.39 (1.08 to 1.79)	0.010
Right wrist extensors	0.90 (0.74 to 1.08)	0.254	0.88 (0.73 to 1.07)	0.193	0.92 (0.77 to 1.11)	0.380	0.73 (0.60 to 0.88)	0.001	0.80 (0.66 to 0.98)	0.029	0.98 (0.79 to 1.22)	0.884
Left hip flexors	0.99 (0.72 to 1.36)	0.964	0.96 (0.73 to 1.28)	0.791	0.85 (0.62 to 1.15)	0.284	0.74 (0.55 to 0.99)	0.040	0.77 (0.56 to 1.06)	0.115	0.90 (0.61 to 1.32)	0.585
Right hip flexors	0.96 (0.69 to 1.34)	0.830	0.95 (0.70 to 1.28)	0.719	1.09 (0.79 to 1.50)	0.613	1.18 (0.87 to 1.62)	0.290	1.18 (0.84 to 1.66)	0.331	1.06 (0.69 to 1.64)	0.788
Left ankle extensors	1.14 (0.93 to 1.40)	0.214	1.13 (0.94 to 1.34)	0.185	1.14 (0.95 to 1.37)	0.166	1.26 (1.04 to 1.52)	0.021	1.09 (0.91 to 1.30)	0.367	0.93 (0.71 to 1.21)	0.583
Right ankle extensors	0.94 (0.76 to 1.15)	0.530	0.95 (0.79 to 1.14)	0.564	0.94 (0.77 to 1.14)	0.539	0.85 (0.70 to 1.04)	0.125	0.81 (0.68 to 0.97)	0.023	0.72 (0.57 to 0.91)	0.007

According to table 1, the MRC score for the neck flexors was commonly identified as a possible prognostic factor for the primary endpoint and the five ADL milestones. We further examined its impact after adjusting for the other established or potential risk factors, that is, age at registration, gender, disease duration from onset to registration, percent vital capacity (% VC) at registration, ALSFRS-R score at registration, classification according to revised El Escorial criteria, riluzole use and bulbar symptom at registration (table 2). As seen in table 2, the MRC score for the neck flexors was an independent and significant prognostic factor for the primary endpoint, *loss of speech*, *loss of swallowing*, *loss of upper-limb function* and *difficulty turning in bed* in patients with ALS except for *loss of walking ability*. ( $p < 0.001$ ,  $p = 0.001$ ,  $p = 0.003$ ,  $p < 0.001$ ,  $p = 0.027$ , respectively). At registration, there were moderate and significant correlations between the MRC score for the neck flexors and the % VC or the ALSFRS-R score. Pearson's correlation coefficients were 0.367 ( $p < 0.001$ ) and 0.496 ( $p < 0.001$ ), respectively.

Differences in survival time and time to ADL milestones in patients in terms of the MRC score grade for the neck flexors We divided the registered patients into four categories according to their MRC score for the neck flexors (ie, 5, 4, 3 and  $\leq 2$ ). Figure 1 shows the Kaplan–Meier curves for the four categories for the primary endpoint and each ADL milestone. All the differences between the curves were significant according to a log-rank test ( $p < 0.001$ ).

## DISCUSSION

In a prospective and multicentre cohort study, we identified that weakness of the neck flexors is a potent factor for the prediction of survival and for the deterioration of ADL, such as speech, swallowing, upper limb function, turning in bed, and walking, in sporadic patients with ALS.

The neck flexors consist of the sternocleidomastoid muscle (SCM), the platysma muscle, hyoid muscle, longus capitis muscle, longus colli and scalenus. These muscles are innervated by motor neurons in the cervical cord (C1–8) and accessory nerve nuclei,<sup>29 30</sup> primarily the C2–4 segments. By contrast, respiratory muscles consist of the diaphragm and the internal and external intercostals muscles, which are innervated by motor neurons of the upper cervical cord (C3–5) and thoracic cord (Th1–Th12), respectively.<sup>30</sup> Thus, the muscles for neck flexion and those for respiration partially share spinal segments of the motor neuron column for their motor innervations. Furthermore, significant correlations are present between compound muscle action potentials of the SCM and those of the diaphragm in patients with ALS,<sup>31</sup> suggesting that neck muscle weakness is correlated with weakness of the diaphragm to some extent in ALS. Because the main cause of death in patients with ALS is respiratory insufficiency, it is reasonable that neck flexor weakness was associated with respiratory impairments and, eventually, survival time. The motor response amplitude of the phrenic nerve motor neurons which are located in the C3–5 segments has been shown to be a significant prognostic factor for survival in patients with ALS.<sup>32</sup> This supports our findings.

Why then is weakness of the neck flexors a determinant factor for the deterioration of ADL for speech, swallowing, upper limb function, truncal turning and walking ability? Recently, some studies have suggested that the degeneration of motor neurons is initially a focal process in ALS that later spreads contiguously throughout the three-dimensional anatomy of connected or neighbouring neurons.<sup>33–36</sup> Dysfunction of speech and swallowing involves the impairment of motor

## Neurodegeneration

Table 2 Multivariate Cox regression analyses with the adjustments of the covariates that we selected for the primary endpoint and each activity of daily living milestone using known predictive factors

	Primary endpoint		Loss of speech		Loss of swallowing function		Loss of upper limb function		Difficulty turning in bed		Loss of walking ability	
	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
MRC score of neck flexors at registration	0.72 (0.62 to 0.83)	<0.001	0.78 (0.67 to 0.90)	0.001	0.80 (0.69 to 0.93)	0.003	0.76 (0.65 to 0.88)	<0.001	0.83 (0.70 to 0.98)	0.027	0.95 (0.79 to 1.15)	0.601
Age at registration (years)	1.03 (1.02 to 1.04)	<0.001	1.02 (1.01 to 1.03)	0.002	1.03 (1.01 to 1.04)	<0.001	1.01 (0.99 to 1.02)	0.264	1.01 (0.99 to 1.02)	0.265	1.00 (0.98 to 1.01)	0.890
Gender (male vs female)	1.14 (0.85 to 1.52)	0.381	0.85 (0.65 to 1.12)	0.247	1.13 (0.85 to 1.49)	0.398	1.27 (0.97 to 1.68)	0.088	1.01 (0.76 to 1.33)	0.947	0.85 (0.61 to 1.17)	0.309
Duration from onset to registration (years)	0.64 (0.57 to 0.72)	<0.001	0.72 (0.64 to 0.80)	<0.001	0.69 (0.62 to 0.77)	<0.001	0.82 (0.75 to 0.9)	<0.001	0.74 (0.65 to 0.85)	<0.001	0.75 (0.66 to 0.87)	<0.001
%VC at registration	0.98 (0.98 to 0.99)	<0.001	0.98 (0.97 to 0.99)	<0.001	0.98 (0.98 to 0.99)	<0.001	0.99 (0.98 to 1.00)	0.001	0.99 (0.99 to 1.00)	0.007	1.00 (0.99 to 1.00)	0.491
ALSFRS-R at registration	0.97 (0.94 to 0.99)	0.008	0.99 (0.97 to 1.02)	0.483	0.96 (0.93 to 0.98)	0.001	0.96 (0.94 to 0.98)	0.001	0.89 (0.86 to 0.92)	<0.001	0.91 (0.88 to 0.94)	<0.001
El Escorial criteria (probable or probable laboratory-supported)	0.72 (0.53 to 0.99)	0.043	0.61 (0.45 to 0.82)	0.001	0.76 (0.56 to 1.04)	0.087	0.67 (0.50 to 0.90)	0.007	0.71 (0.52 to 0.97)	0.031	0.63 (0.44 to 0.88)	0.008
Riluzole administration	1.02 (0.75 to 1.37)	0.916	1.09 (0.82 to 1.44)	0.551	0.97 (0.73 to 1.29)	0.843	0.95 (0.72 to 1.25)	0.694	0.84 (0.63 to 1.13)	0.258	0.94 (0.68 to 1.31)	0.721
Bulbar symptom at registration	0.91 (0.67 to 1.22)	0.524	2.04 (1.52 to 2.73)	<0.001	1.41 (1.06 to 1.86)	0.018	0.68 (0.50 to 0.93)	0.015	0.63 (0.47 to 0.84)	0.002	0.68 (0.49 to 0.96)	0.028

%VC, percent vital capacity; ALSFRS-R, revised amyotrophic lateral sclerosis functional rating scale.

neurons relayed via the glossopharyngeal, vagus, accessory and hypoglossal nerves to the medulla oblongata.<sup>30</sup> The medulla oblongata and cervical cord motor neurons innervating the neck flexion muscles are anatomically different in their three-dimensional layering, while these two groups of neurons are rather contiguously located. Thus, it may be speculated that if the contiguous spreading of motor neuron degeneration occurs according to the local spreading hypothesis, neck flexion impairment may eventually affect speech and swallowing functions. Furthermore, motor neurons for the neck flexion muscles, which are located in the C1–8 segments,<sup>29 30</sup> are also contiguous or overlapping with those for the upper limb muscles in the C5–Th1 segments, particularly the proximal upper limb muscles.<sup>29 30</sup> Neck flexion and upper limb function may be correlated with disease progression through the local spreading view of motor neuron degeneration. Truncal turning and walking require not only lower limb muscle activities but also power in a broad area of the chest, abdominal and back muscles, which are innervated by the cervical to lumbar cord.<sup>37–39</sup> Therefore, propagation of weakness from the cervical and lumbar areas may affect truncal turning or walking. We need, however, further investigations to demonstrate the underlying mechanisms of the correlation between the neck muscles and other muscles of the body that together determine ADL.

In this study, the MRC score for the left wrist extensors shows a positive prognostic factor for the primary endpoint and some ADL milestones, the reason for which might be that the weakness of the distal muscle in the non-dominant arm was least relevant to survival, or ADL declines so that it was shown to be a positive factor in the multivariate analyses.

A number of studies have demonstrated survival curves for patients with ALS and some factors that influence these survival curves.<sup>18</sup> The majority of these studies have found that older age is a strong risk factor for shorter survival in patients with ALS,<sup>6–10</sup> and the onset of bulbar symptoms is associated with a worse prognosis than the onset of spinal symptoms.<sup>6 7</sup> Several studies have found that a longer diagnostic delay correlates with a better prognosis,<sup>2 6 10 13 14</sup> and that a lower %VC or a percent forced vital capacity (%FVC) is correlated with shorter survival for patients with ALS.<sup>3 8 11 12</sup> The progression rate of the ALSFRS-R at the time of diagnosis was also related to ALS prognosis.<sup>17</sup> Neck flexor weakness has not been listed as a prognostic factor for patients with ALS, and most of these studies evaluated survival alone as an endpoint, and did not determine the onset of loss of speech, swallowing, limb and truncal function. In this study, we showed that neck flexor weakness was not only a novel prognostic factor for survival but also a significant prognostic marker for non-survival events related to ADL decline for patients with ALS.

In the course of ALS, patients must make some difficult decisions, including the use of gastrostomy for tube feeding, the use of assisted ventilation, and end-of-life planning, which require the support of the attending physician and a multidisciplinary team. All patients with ALS should be provided with sufficient information concerning these interventions and given sufficient opportunity for the careful consideration of their decision. In the medical, nursing and social care of patients with ALS, simple and robust indicators for predicting the status of each patient for several months or a year after diagnosis are necessary for patient management. Medical staff and caregivers need to have a predictor of the patient's status in the near future, including survival prognosis and also estimates for the loss of speech, swallowing, limb and truncal function. Our findings may contribute to such prediction.




Figure 1 Kaplan–Meier curves according to the MRC score for the neck flexors. The Kaplan–Meier curves for the primary endpoint and each activity of daily living milestone among four categories divided according to the MRC score for the neck flexors were compared by the log-rank test. Curves are shown for the MRC score 5 (blue), the MRC score 4 (green), the MRC score 3 (orange), and the MRC score  $\leq 2$  (purple) groups. All the differences of the curves were significant ( $p < 0.001$ ).

The course of ALS is highly variable between patients,<sup>5</sup> which is one of the major factors limiting the power of ALS clinical trials.<sup>40–41</sup> Therefore, robust stratification factors that could divide ALS patient groups depending upon prognosis are needed for designing trials. Compared with known prognostic factors for patients with ALS, such as age, duration from onset to registration, ALSFRS-R at registration, and presence of bulbar symptom, weakness of the neck flexors was a potent and independent

prognostic factor. Thus, the MRC score for the neck flexors might be used for stratification factor in a future clinical trial.

Neck extensor muscle weakness with head drop as an early symptom has been reported in a few patients with ALS.<sup>42–43</sup> However, Katz *et al*<sup>44</sup> wrote that neck flexor weakness is typically observed. We assert that neck flexor weakness is commonly observed in patients with ALS, and is useful for the prediction of prognosis.

## Neurodegeneration

The limitations of this study are as follows: registered patients were followed-up by telephone survey, and we did not examine longitudinal changes in the strength of multiple muscles. As we demonstrated, the relationship between the involved muscle groups and survival prognosis and estimates of ADL deterioration would offer insights into the modalities of progression in patients with ALS. However, to examine the pattern of spread more precisely, a cohort study that observes longitudinal changes in the strength of muscle groups and extensions of muscle weakness will be required.

This study analysed a multicentre cohort of patients with ALS in a single nation, Japan. Although the clinical profiles of ALS are broadly similar among countries in previous reports, the outcome of our study would be better confirmed in cohorts of patients with ALS in multiple countries.

In conclusion, we showed that neck weakness is an independent prognostic factor for survival and deterioration in ADL in patients with ALS. We hope that our report will be helpful for clinicians who want to provide medical, social and nursing care to patients with ALS with proper timing, and to researchers as they plan clinical trials for ALS.

### Author affiliations

<sup>1</sup>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan

<sup>2</sup>Biostatistics Section, Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan

<sup>3</sup>Department of Neurology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

<sup>4</sup>Department of Clinical Neuroscience, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan

<sup>5</sup>Division of Neurology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan

<sup>6</sup>Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan

<sup>7</sup>Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan

<sup>8</sup>Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan

<sup>9</sup>Department of Neurology, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan

<sup>10</sup>Department of Neurology, Gunma University Graduate School of Medicine, Gunma, Japan

<sup>11</sup>Division of Neurology, National Hospital Organization, Sagami National Hospital, Sagami, Japan

<sup>12</sup>Department of Neurology, Tohoku University School of Medicine, Sendai, Japan

<sup>13</sup>Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan

<sup>14</sup>Department of Neurology, Okayama University Graduate School of Medicine, Okayama, Japan

<sup>15</sup>Department of Neurology, Vihara Hananosato Hospital, Miyoshi, Japan

<sup>16</sup>Department of Neurology, National Hospital Organization, Suzuka National Hospital, Suzuka, Japan

<sup>17</sup>Division of Neurology, National Hospital Organization, Miyagi National Hospital, Miyagi, Japan

<sup>18</sup>Director of North Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan

<sup>19</sup>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

**Acknowledgements** We thank all Patients with ALS who participated in this study. We also thank all participating doctors and staff of JaCALS.

**Collaborators** JaCALS members included Drs Tatsuhiko Yuasa (Kamagaya General Hospital); Takahiro Kano (Hokkaido University); Hidenao Sasaki (Hokkaido University); Masaaki Kato (Tohoku University); Tomohiko Ishihara (Niigata University); Masatoyo Nishizawa (Niigata University); Masaki Ikeda (Gunma University); Kazumoto Shibuya (Chiba University); Satoshi Kuwabara (Chiba University); Hideaki Hayashi, MD (Tokyo Metropolitan Neurological Hospital); Yuji Takahashi (The University of Tokyo); Hiroyuki Tomiyama (Juntendo University); Nobutaka Hattori (Juntendo University); Hitoshi Aizawa (Tokyo National Hospital); Osamu Kano (Toho University Omori Medical Center); Yasuo Iwasaki (Toho University Omori Medical Center); Takamura Nagasaka (University of Yamanashi); Yoshihisa Takiyama (University of Yamanashi); Motoko Sakai (Suzuka National Hospital); Kensuke Shiga (Kyoto Prefectural University); Hirofumi Yamashita (Kyoto University); Ryosuke Takahashi (Kyoto University); Takuji Fujita (Takumikai Neurology Clinic); Toru

Yamashita (Okayama University); Masanori Hiji (Vihara Hananosato Hospital); Yasuhiro Watanabe (Tottori University); Kenji Nakashima (Tottori University); Shintaro Hayashi (Kyushu University); and Jun-ichi Kira (Kyushu University).

**Contributors** RN: drafting/revising the manuscript, acquisition, analysis and interpretation of the data, statistical analysis, and research project execution; NA: drafting/revising the manuscript, acquisition, analysis and interpretation of the data, statistical analysis, research project execution, and study design and concept; HaW: acquisition and interpretation of the data, and research project execution; AH: manuscript review and critique, analysis and interpretation of the data, and statistical analysis design; HiW and MI: acquisition and interpretation of the data, research project execution, and study design and concept; JS, MKatsu, FT, Yul, KotO, AT, IA, KM, KoiO, KH, AK, KA, MO, MKo, Tal, MNa, and IN: revising the manuscript, and acquisition and interpretation of the data; MM, MA, ST, and RK: revising the manuscript, acquisition and interpretation of the data, and the members of the JaCALS steering committee; GS: research project organisation and execution, drafting/revising the manuscript, interpretation of the data, study design and concept, and the member of the JaCALS steering committee. TY: the member of the JaCALS steering committee; TK, HS, MKato, Tol, MNi, MI, KaS, SK, HH, YuT, HT, NH, HA, OK, Yal, TN, YaT, MS, KeS, HY, RT, TF, TY, MH, YW, KN, SH, and JK: acquisition of the data.

**Funding** This study was supported by Health and Labour Sciences Research grants (Research on intractable diseases H23-015 and H24-012) and grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (grant number 25461277).

**Competing interests** None.

**Ethics approval** The ethics committees of all the participating institutions approved the study.

**Provenance and peer review** Not commissioned; externally peer reviewed.

### REFERENCES

- Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. *N Engl J Med* 2001;344:1688–700.
- Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. *Brain* 1995;118:707–19.
- Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. *Neurology* 1993;43:1316–22.
- Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. *J Neurol Sci* 1993;118:48–55.
- Chio A, Calvo A, Moglia C, et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. *J Neurol Neurosurg Psychiatry* 2011;82:740–6.
- del Aguila MA, Longstreth WT Jr, McGuire V, et al. Prognosis in amyotrophic lateral sclerosis: a population-based study. *Neurology* 2003;60:813–19.
- Magnus T, Beck M, Giess R, et al. Disease progression in amyotrophic lateral sclerosis: predictors of survival. *Muscle Nerve* 2002;25:709–14.
- Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. *Neurology* 2002;59:99–103.
- Christensen PB, Hojer-Pedersen E, Jensen NB. Survival of patients with amyotrophic lateral sclerosis in 2 Danish counties. *Neurology* 1990;40:600–4.
- Millul A, Beghi E, Logroscino G, et al. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. *Neuroepidemiology* 2005;25:114–19.
- Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. *Neurology* 1998;50:66–72.
- Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. *J Neurol Neurosurg Psychiatry* 2006;77:390–2.
- Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. *J Neurol* 2006;253:1428–36.
- Kaufmann P, Levy G, Thompson JL, et al. The ALSFRS-r predicts survival time in an ALS clinic population. *Neurology* 2005;64:38–43.
- Armon C, Graves MC, Moses D, et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. *Muscle Nerve* 2000;23:874–82.
- Armon C, Moses D. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials. *J Neurol Sci* 1998;160(Suppl 1): S37–41.
- Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. *Neurology* 2006;66:265–7.
- Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. *Amyotroph Lateral Scler* 2009;10:310–23.
- Medical Research Council. *Aids to the examination of the peripheral nervous system*. London: Her Majesty's Stationery Office, 1976.
- Campbell WW. *Dejong's Neurologic Examination*. Philadelphia, USA: Lippincott Williams & Wilkins, 2005.

- 21 Brooks BR, Miller RG, Swash M, *et al*. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000;1:293–9.
- 22 Ohashi Y, Tashiro K, Itoyama Y, *et al*. Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS-R (ALSFRS-R) Japanese version. *No To Shinkei* 2001;53:346–55.
- 23 Atsuta N, Watanabe H, Ito M, *et al*. Development of a telephone survey system for patients with amyotrophic lateral sclerosis using the ALSFRS-R (Japanese version) and application of this system in a longitudinal multicenter study. *Brain Nerve* 2011;63:491–6.
- 24 Kasarskis EJ, Dempsey-Hall L, Thompson MM, *et al*. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2005;6:50–4.
- 25 Kaufmann P, Levy G, Montes J, *et al*. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. *Amyotroph Lateral Scler* 2007;8:42–6.
- 26 Mannino M, Cellura E, Grimaldi G, *et al*. Telephone follow-up for patients with amyotrophic lateral sclerosis. *Eur J Neurol* 2007;14:79–84.
- 27 Chancellor AM, Slattery JM, Fraser H, *et al*. The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. *J Neurol* 1993;240:339–46.
- 28 Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev* 2012;3:CD001447.
- 29 Brendler SJ. Human cervical myotomes—functional anatomy studied at operation. *J Neurosurg* 1968;28:105–11.
- 30 Parent A. *Carpenter's human neuroanatomy*. Quebec, Canada: Williams & Wilkins, 1996.
- 31 Pinto S, de Carvalho M. Motor responses of the sternocleidomastoid muscle in patients with amyotrophic lateral sclerosis. *Muscle Nerve* 2008;38:1312–17.
- 32 Pinto S, Pinto A, de Carvalho M. Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. *Clin Neurophysiol* 2012;123:2454–9.
- 33 Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. *Neurology* 2009;73:805–11.
- 34 Fujimura-Kiyono C, Kimura F, Ishida S, *et al*. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2011;82:1244–9.
- 35 Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? *J Neurol Neurosurg Psychiatry* 2012;83:739–45.
- 36 Brettschneider J, Tredici KD, Toledo JB, *et al*. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. *Ann Neurol* Published Online First: 20 May 2013. doi:10.1002/ana.23937.
- 37 Kavanagh J, Barrett R, Morrison S. The role of the neck and trunk in facilitating head stability during walking. *Exp Brain Res* 2006;172:454–63.
- 38 Ballesteros ML, Buchthal F, Rosenfalck P. The pattern of muscular activity during the arm swing of natural walking. *Acta Physiol Scand* 1965;63:296–310.
- 39 Richter RR, VanSant AF, Newton RA. Description of adult rolling movements and hypothesis of developmental sequences. *Phys Ther* 1989;69:63–71.
- 40 Cudkovicz ME, Katz J, Moore DH, *et al*. Toward more efficient clinical trials for amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 2010;11:259–65.
- 41 Sorenson EJ. What is next in ALS clinical trials? *Neurology* 2007;69:719–20.
- 42 Gourie-Devi M, Nalini A, Sandhya S. Early or late appearance of “dropped head syndrome” in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2003;74:683–6.
- 43 Uemura M, Kosaka T, Shimohata T, *et al*. Dropped head syndrome in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degeneration* 2013;14:232–3.
- 44 Katz JS, Wolfe GI, Burns DK, *et al*. Isolated neck extensor myopathy: a common cause of dropped head syndrome. *Neurology* 1996;46:917–21.





## Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients

Ryoichi Nakamura, Naoki Atsuta, Hazuki Watanabe, Akihiro Hirakawa, Hirohisa Watanabe, Mizuki Ito, Jo Senda, Masahisa Katsuno, Fumiaki Tanaka, Yuishin Izumi, Mitsuya Morita, Kotaro Ogaki, Akira Taniguchi, Ikuko Aiba, Koichi Mizoguchi, Koichi Okamoto, Kazuko Hasegawa, Masashi Aoki, Akihiro Kawata, Koji Abe, Masaya Oda, Masaaki Konagaya, Takashi Imai, Masanori Nakagawa, Shoji Tsuji, Ryuji Kaji, Imaharu Nakano and Gen Sobue

*J Neurol Neurosurg Psychiatry* 2013 84: 1365-1371 originally published online August 9, 2013  
doi: 10.1136/jnnp-2013-306020

---

Updated information and services can be found at:  
<http://jnnp.bmj.com/content/84/12/1365>

---

*These include:*

**Supplementary Material** Supplementary material can be found at:  
<http://jnnp.bmj.com/content/suppl/2013/08/09/jnnp-2013-306020.DC1.html>

**References** This article cites 40 articles, 7 of which you can access for free at:  
<http://jnnp.bmj.com/content/84/12/1365#BIBL>

**Email alerting service** Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

**Topic Collections** Articles on similar topics can be found in the following collections

- Motor neurone disease (268)
- Neuromuscular disease (1211)
- Spinal cord (485)
- Musculoskeletal syndromes (495)

---

### Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>

## Loss of TDP-43 causes age-dependent progressive motor neuron degeneration

Yohei Iguchi,<sup>1</sup> Masahisa Katsuno,<sup>1</sup> Jun-ichi Niwa,<sup>2</sup> Shinnosuke Takagi,<sup>1</sup> Shinsuke Ishigaki,<sup>1</sup> Kensuke Ikenaka,<sup>1</sup> Kaori Kawai,<sup>1</sup> Hirohisa Watanabe,<sup>1</sup> Koji Yamanaka,<sup>3,4</sup> Ryosuke Takahashi,<sup>5</sup> Hidemi Misawa,<sup>6</sup> Shoichi Sasaki,<sup>7</sup> Fumiaki Tanaka<sup>1,8</sup> and Gen Sobue<sup>1,4</sup>

1 Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan

2 Stroke Centre, Aichi Medical University, Aichi 480-1195, Japan

3 Laboratory for Motor Neuron Disease, RIKEN Brain Science Institute, Wako, Saitama 351-0198, Japan

4 CREST, Japan Science and Technology Agency, 4-1-8, Honcho, Kawaguchi, Saitama 332-0012, Japan

5 Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan

6 Department of Pharmacology, Keio University Faculty of Pharmacy, Tokyo 105-8512, Japan

7 Department of Neurology, Neurological Institute, Tokyo Women's Medical University, Tokyo 162-8666, Japan

8 Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan

Correspondence to: Gen Sobue

Showa-ku, Nagoya 466-8550,

Japan

E-mail: sobueg@med.nagoya-u.ac.jp

Amyotrophic lateral sclerosis is a devastating, progressive neurodegenerative disease that affects upper and lower motor neurons. Although several genes are identified as the cause of familial cases, the pathogenesis of sporadic forms, which account for 90% of amyotrophic lateral sclerosis, have not been elucidated. Transactive response DNA-binding protein 43 a nuclear protein regulating RNA processing, redistributes to the cytoplasm and forms aggregates, which are the histopathological hallmark of sporadic amyotrophic lateral sclerosis, in affected motor neurons, suggesting that loss-of-function of transactive response DNA-binding protein 43 is one of the causes of the neurodegeneration. To test this hypothesis, we assessed the effects of knockout of transactive response DNA-binding protein 43 in mouse postnatal motor neurons using Cre/loxP system. These mice developed progressive weight loss and motor impairment around the age of 60 weeks, and exhibited degeneration of large motor axon, grouped atrophy of the skeletal muscle, and denervation in the neuromuscular junction. The spinal motor neurons lacking transactive response DNA-binding protein 43 were not affected for 1 year, but exhibited atrophy at the age of 100 weeks; whereas, extraocular motor neurons, that are essentially resistant in amyotrophic lateral sclerosis, remained preserved even at the age of 100 weeks. Additionally, ultra structural analysis revealed autolysosomes and autophagosomes in the cell bodies and axons of motor neurons of the 100-week-old knockout mice. In summary, the mice in which transactive response DNA-binding protein 43 was knocked-out specifically in postnatal motor neurons exhibited an age-dependent progressive motor dysfunction accompanied by neuropathological alterations, which are common to sporadic amyotrophic lateral sclerosis. These findings suggest that transactive response DNA-binding protein 43 plays an essential role in the long term maintenance of motor neurons and that loss-of-function of this protein seems to contribute to the pathogenesis of amyotrophic lateral sclerosis.

**Keywords:** transactive response DNA-binding protein 43; amyotrophic lateral sclerosis; axonal degeneration; autophagosome

**Abbreviations:** ALS = amyotrophic lateral sclerosis; FTL = frontotemporal lobar degeneration; TDP CKO = motor neuron-specific TDP-43 knockout; TDP hCKO = TDP heterozygous CKO

Received July 20, 2012. Revised December 17, 2012. Accepted December 28, 2012. Advance Access publication February 28, 2013

© The Author (2013). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.

For Permissions, please email: journals.permissions@oup.com

## Introduction

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease that affects upper and lower motor neurons in the brain stem and spinal cord. Although previous studies using animal models of ALS have focused mainly on the toxicity of mutant SOD1, one of the causative genes of familial ALS (ALS1), there are pathophysiological differences between ALS1 and sporadic ALS that accounts for ~90% of ALS. The most striking recent discovery regarding ALS is that transactive response DNA-binding protein 43 (TDP-43) was identified as a major component of ubiquitinated neuronal cytoplasmic inclusions in both sporadic ALS and frontotemporal lobar degeneration (FTLD) (Arai *et al.*, 2006; Neumann *et al.*, 2006). In addition, TDP-43 is a causative gene of familial ALS (ALS10) (Gitcho *et al.*, 2008; Kabashi *et al.*, 2008; Sreedharan *et al.*, 2008; Yokoseki *et al.*, 2008). Taken together, these data suggest that TDP-43 plays a key role in the pathogenesis of sporadic ALS. Although TDP-43 is a nuclear protein, it redistributes to the cytoplasm and forms aggregates in affected neurons of patients with sporadic ALS (Arai *et al.*, 2006; Neumann *et al.*, 2006), suggesting that loss of TDP-43 function underlies sporadic ALS pathogenesis. TDP-43 is known to regulate gene transcription, stability of messenger RNA, and exon splicing through interactions with RNA, heterogeneous nuclear ribonucleoproteins and nuclear bodies (Wang *et al.*, 2004; Ayala *et al.*, 2005; Buratti *et al.*, 2005, 2010; Strong *et al.*, 2007; Polymenidou *et al.*, 2011; Sephton *et al.*, 2011; Tollervey *et al.*, 2011). Knockdown of TDP-43 in neuronal cells inhibits neurite outgrowth and diminishes cell viability (Iguchi *et al.*, 2009), whereas TDP-43 depletion induces apoptosis in HeLa or U2OS cells (Ayala *et al.*, 2008). In addition, *Drosophila* without TDP-43 present deficient locomotive behaviours, reduced life span and anatomical defects at neuromuscular junctions (Feiguin *et al.*, 2009). TDP-43-depleted zebrafish exhibit swimming deficits along with excessive, premature branching and shortened motor axons (Kabashi *et al.*, 2011). Furthermore, TDP-43 knockout mice are embryonic lethal (Kraemer *et al.*, 2010; Sephton *et al.*, 2010; Wu *et al.*, 2010), and postnatal deletion of TDP-43 leads to rapid death with loss of body fat (Chiang *et al.*, 2010). Although these findings indicate that TDP-43 is essential for survival of mice at both embryonic and post-natal stages, the effects of TDP-43 depletion in postnatal mammalian neurons have not been fully elucidated. In the present study, we generated motor neuron-specific TDP-43 knockout (TDP CKO) mice using the Cre/loxP recombination system to investigate the effects of TDP-43 loss on postnatal motor neurons in mice.

## Materials and methods

### Generation and maintenance of TDP-43 conditional knockout mouse

The targeting construct was designed to insert an Frt-flanked neomycin cassette and a loxP site upstream, and a loxP site downstream of the second exon of the *Tardbp* gene. This construct was

electroporated into iTL1 BA1 (C57BL/6 × 129/SvEv) hybrid embryonic stem cells. Correctly targeted embryonic stem cells were injected into recipient blastocysts and chimeric mice were bred with C57BL/6J mice. The resulting En1flox-neo mice were then bred to C57BL/6J mice constitutively expressing Flp recombinase to remove the Frt-flanked neo cassette, generating En1flox offspring. En1flox mutant mice were backcrossed with C57BL/6J mice for at least five generations, and then crossed with VAcHT-Cre.Fast mice, which are the most validated mice that specifically express Cre in motor neurons (Misawa *et al.*, 2003). To generate TDP-43 conditional knockout mice, we crossed TDP-43<sup>flox/flox</sup> mice with TDP-43<sup>flox/+</sup>/VAcHT-Cre mice. Finally, we obtained TDP-43<sup>flox/flox</sup>/VAcHT-Cre (motor neuron-specific TDP-43 knockout: TDP CKO), TDP-43<sup>flox/+</sup>/VAcHT-Cre (TDP heterozygous CKO: TDP hCKO), TDP-43<sup>flox/flox</sup> and TDP-43<sup>flox/+</sup> mice. The TDP-43<sup>flox/flox</sup> mice were then used as control littermates in the present analyses. Mice were kept on a 12-h light/12-h dark cycle, with food and water provided *ad libitum*. All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and under the approval of the Nagoya University Animal Experiment Committee (Nagoya, Japan).

### Neurological and behavioural testing

The control ( $n = 21$ ) and TDP CKO ( $n = 20$ ) mice were subjected to the Rotarod task (Economex Rotarod; Columbus Instruments) weekly as described previously (Katsuno *et al.*, 2002). Grip strength was measured weekly by a grip strength meter (MK-380M, Muromachi kikai Co. LTD). During this test, the mice gripped the mesh with four limbs and their tail was pulled backwards. Gait stride was measured from 50 cm of footsteps, and the average value was recorded for each mouse.

### Immunofluorescent analysis and immunohistochemistry

For immunofluorescent analysis, we perfused 20 ml of a 4% paraformaldehyde fixative in phosphate buffer (WAKO Corp.) through the left cardiac ventricle of mice deeply anaesthetized with medetomidine (0.3 mg/kg), midazolam (4 mg/kg) and butorphanol (5 mg/kg), intraperitoneally. Tissues postfixed overnight in 10% phosphate-buffered formalin were then processed for paraffin embedding. We then deparaffinized 3- $\mu$ m thick tissue sections and dehydrated them with alcohol. Sections were first microwaved for 20 min in 50 mM citrate buffer (pH 6.0), treated with TNB blocking buffer (PerkinElmer) and incubated overnight with anti-TDP-43 rabbit polyclonal antibody (1:1000, ProteinTech), anti-choline-acetyltransferase (ChAT) goat polyclonal antibody (1:100, Milipore), anti-microtubule-associated protein 1 light chain 3 (LC3) mouse monoclonal antibody (1:1000, MBL), phosphorylated neurofilament-H (pNF-H) mouse monoclonal antibody (SMI31) (1:1000, Covance), or anti-neuronal nuclei (NeuN) mouse monoclonal antibody (1:100, Millipore). After washing, for the ChAT staining, sections were incubated with biotinylated donkey anti-goat IgG (1:300, Vector Lab.) for 30 min, washed and incubated with streptavidin conjugated with Alexa Fluor<sup>®</sup> 546 (1:1000, Invitrogen) for 30 min. For the other antigens, sections were incubated with the indicated secondary antibody and TO-PRO<sup>®</sup>3 (Invitrogen), a nuclear marker, for 30 min, mounted with ProLong<sup>®</sup> Gold Antifade reagent (Invitrogen), and then imaged with a laser confocal microscope (LSM710, Carl Zeiss). For immunohistochemistry, sections were incubated overnight with anti-gial fibrillary acidic protein (GFAP) mouse

monoclonal antibody (1:1000, Sigma-Aldrich), stained using the DAKO EnVision™+ HRP system (Dako Corp.) and photographed with an optical microscope (Axio Imager M1). The immunoreactive area in the ventral horn of TDP CKO mice and control littermates at the indicated ages ( $n = 3$  for each age) was analysed with WinROOF (Mitani). The binary treatment included application of a staining intensity threshold and size exclusion criteria to distinguish the significant structures from the background signals. All sections analysed were treated with the same threshold and exclusion criteria.

## Retrograde FluoroGold neurotracer labelling

Retrograde labelling of motor neurons was performed as described previously (Katsuno *et al.*, 2006). Briefly, a total volume of 4.5  $\mu$ l of 2.5% FluoroGold solution (Biotium) was injected into the gastrocnemius muscle of anaesthetized mice. Lumbar spinal cords were removed 46 h after FluoroGold administration. The frozen optimal cutting temperature (OCT) compound-embedded samples were sectioned longitudinally on a cryostat at 10  $\mu$ m and mounted on silane-coated slides. After the FluoroGold labelled motor neurons in the L5 segment was photographed with Zeiss Axio Imager M1 (Carl Zeiss), the sections were fixed with 4% paraformaldehyde, stained with anti-TDP-43 and anti-ChAT antibody, and photographed with LSM710. For the quantification of retrograde labelling, we measured every third section (a total of five sections in L5 ventral horn), and counted the degree of FluoroGold labelling in motor neurons of two control mice, and TDP-43-positive or -negative motor neurons of two TDP CKO mice.

## Electron microscopy

Under the deep anaesthesia, 2-year-old TDP CKO mice and control littermates were transcardially perfused with 3% paraformaldehyde and 1% glutaraldehyde in PBS. The spinal cords and sciatic nerves were removed, and postfixed overnight in the perfusing solution. After fixation, the spinal cords were immersed in the solution (0.1 M cacodylic acid, 2% paraformaldehyde, 2.5% glutaraldehyde) for 12 h. The anterior half of lumbar spinal cord was sectioned transversely, postfixed in 1% osmium tetroxide for several hours, dehydrated and embedded in epoxy resin. Each block was cut into serial semithin sections (~1- $\mu$ m thick). These sections were stained with toluidine blue. Appropriate portions of the sections were cut into ultrathin sections, which were then stained with uranyl acetate and lead citrate. Two-year-old TDP CKO mice and control littermates were analysed. Electron microscopic photographs were obtained under an original magnification of  $\times 5000$  and printed at a final magnification of  $\times 9500$ .

## Analysis of muscle, neuromuscular junction and motor axon

To investigate the presence of muscle atrophy, gastrocnemius muscles were dissected free, quickly frozen by immersion in cooled acetone and powdered CO<sub>2</sub>. Ten-micrometre thick transverse frozen sections were stained with haematoxylin and eosin. For analysis of neuromuscular junctions, 30- $\mu$ m thick frozen longitudinal sections of the tibialis anterior muscle were incubated overnight with alpha bungarotoxin conjugated with biotin-XX (1:80, Invitrogen), anti-pNF-H mouse monoclonal antibody (SMI31, 1:100) and anti-synaptophysin rabbit polyclonal antibody (1:100, Cell Signaling Technologies). After washing, sections were incubated with goat anti-rabbit and anti-mouse IgG

conjugated with Alexa Fluor® 488 (1:1000 for each, Invitrogen) and streptavidin conjugated with Alexa Fluor® 564 (1:1000, Invitrogen) and mounted with ProLong® gold (Invitrogen). The stained sections were imaged with a laser scanning confocal microscope (LSM710, Carl Zeiss). More than 100 neuromuscular junctions from TDP CKO mice aged 20, 50, 80 and 100 weeks were analysed ( $n = 3$  mice for each group). For morphological analyses, epoxy resin embedded transverse sections of L5 ventral roots were stained with toluidine blue. L5 ventral roots of 20, 50 and 100 week-old mice ( $n = 6$  axons for each group) were assessed. The diameter of myelinated fibres was automatically measured using a computer-assisted image analyser (Luzex FS), as described previously (Katsuno *et al.*, 2002). Paraffin embedded transverse sections of L4 ventral roots of 100-week-old mice were stained with an antibody against ChAT and photographed by Zeiss Axio Imager M1.

## Quantification and morphological analysis of motor neurons

For the quantifications and morphological analyses of motor neurons, we performed the immunofluorescent analyses of the paraffin-embedded sections stained with anti-TDP-43 and anti-ChAT antibodies of L5 spinal cord ( $n = 5$  for each) and brain stem ( $n = 3$  for each) of control and TDP CKO mice. All the neurons within the every fifth sections from the 50 consecutive sections of lumbar spinal cord, or every third sections from all consecutive sections of brain stem including the each cranial motor nucleus were assessed using AxioVision software (Carl Zeiss), after samples were photographed by Zeiss Axio Imager M1 (Carl Zeiss). The ChAT-positive neurons in the ventral horns or cranial nuclei were regarded as motor neurons. We examined the presence of nuclear immunoreactivity for TDP-43 in ventral horns and brainstems, and calculated the TDP-43-knockout efficiencies, the number of remaining motor neurons, and the size of motor neurons in each group. To evaluate the involvement of gamma-motor neuron, we measured the number of large (>250  $\mu$ m<sup>2</sup>) or small (<250  $\mu$ m<sup>2</sup>) lumbar motor neurons.

## Statistical analyses

Statistical differences were analysed by Kaplan–Meier and logrank test for survival rate, ANOVA and Bonferroni *post hoc* analyses for multiple group comparisons and the unpaired Student's *t*-test for two group comparisons (SPSS version 15.0, SPSS Inc.).


## Results

### Generation of TDP CKO mice

We constructed a TDP-43floxed allele by flanking the second exon of the mouse TDP-43 gene (*Tardbp*) with loxP sites (Supplementary Fig. 1A and B). Because the second exon contains the *Tardbp* start codon, Cre-mediated deletion of this exon inhibits mouse TDP-43 translation. To delete TDP-43 expression specifically in motor neurons, TDP-43<sup>flax/flax</sup> mice were crossed with VACHT-Cre.Fast mice, in which Cre expression is mostly restricted in the postnatal somatomotor neurons (Misawa *et al.*, 2003). The immunofluorescent analysis of the ventral horn from TDP CKO mice at post-natal Day 2 showed that all the assessed motor neurons were positive for TDP-43 (Supplementary Fig. 1C). On

the other hand, the quantitative analysis of the lumbar ventral horn and hypoglossal nucleus from 10-week-old TDP CKO mice revealed that TDP-43 was knocked-out in 48% of motor neurons in the lumbar ventral horn and 45% in the hypoglossal nucleus (Fig. 1A and B). In addition, reverse transcriptase PCR analysis of total RNA from motor neurons isolated by laser microdissection,

revealed that exon 2 of *Tarbdp* was partially skipped under the Cre expression (Supplementary Fig. 1D and E). Immunoblot analysis showed that the TDP-43 protein expressions in liver, kidney, heart, skeletal muscle and cerebral cortex of TDP CKO mice were not altered compared with their control littermates (Supplementary Fig. 1F). Immunofluorescent analysis of the



**Figure 1** Progressive motor dysfunction in TDP CKO mice. (A) Immunofluorescent stainings (TDP-43; green, ChAT; red, TO-PRO3; blue) of lumbar ventral horn and hypoglossal nucleus of 10-week-old control and TDP CKO mice. (B) Percentage of TDP-43-positive motor neurons in the lumbar ventral horn and hypoglossal nucleus (N.) of 10-week-old control (Ctl) and TDP CKO mice ( $n = 3$  for each group). (C–E) Body weight (C), Rotarod task (D), and grip strength (E) phenotypes of control (red line,  $n = 21$ ) and TDP CKO mice (blue line,  $n = 20$ ). Error bars indicate SEM. (F) Survival rates of control ( $n = 27$ ) and TDP CKO mice ( $n = 26$ ). (G) The average length of hindpaw steps in 20-week-old ( $n = 6$  for each), 50-week-old ( $n = 6$  for each), and 100-week-old ( $n = 15$  for each) control and TDP CKO mice. Error bars indicate SD. Scale bars: A = 50  $\mu$ m; G = 5 cm. N.S. = not significant.

lumbar dorsal horn of 10-week-old control, TDP CKO and TDP hCKO mouse showed that all the assessed neurons were positive for TDP-43 (Supplementary Fig. 2). In addition, the analyses of 100-week-old control, TDP CKO and TDP hCKO mice demonstrated that TDP-43 was not excised in the neurons of the primary motor cortex, putamen, deep cerebellar nucleus and cerebellar cortex of TDP CKO or TDP hCKO mouse (Supplementary Figs 3 and 4).


## TDP-43 CKO mice develop progressive motor dysfunction

The earliest symptom of motor deficit in TDP CKO mice was tremor, which appeared as early as 50 weeks. TDP CKO mice exhibited progressive weight loss beginning ~60 weeks (Fig. 1C), when muscle atrophy of the trunk and hind limb was detectable. The grip strength and motor performances in the Rotarod task of TDP CKO mice were lower than their control littermates (Fig. 1D and E) beginning at 85 and 75 weeks, respectively. At 100 weeks, TDP CKO mice were significantly different from the control littermates in body weight ( $P = 0.04$ ), rotarod ( $P = 0.001$ ) and grip strength ( $P = 0.002$ ). The average length of hindpaw steps of TDP CKO mice was significantly shorter than that of control littermates in 100 weeks of age ( $P = 0.000001$ ; Fig. 1G). The survival rate of TDP CKO mice, however, was not altered compared with that of control littermates (Fig. 1F). Analyses of TDP-43<sup>fllox/+</sup> and TDP-43<sup>fllox/+</sup>/VChT-Cre (TDP hCKO) mice, which resulted in heterozygous loss of TDP-43 in motor neurons, showed that body weight, Rotarod task, grip strength and length of hindpaw steps were not significantly

different between the two transgenic groups (Supplementary Fig. 5A–D).

## TDP-43 depletion leads to atrophy of spinal motor neurons

Because TDP CKO mice exhibited progressive motor impairment, we focused on the morphology of spinal motor neurons. The immunofluorescent analysis of the lumbar ventral horn in 100-week-old TDP CKO mice revealed that motor neurons without TDP-43 were significantly smaller than those with TDP-43 and those in control littermates (Fig. 2A–C). Although TDP-43 was knocked-out in 49% of motor neurons in TDP CKO mice, the number of motor neurons in TDP CKO mice did not differ from that in control littermates (Fig. 2D and E). A time course analysis of TDP-43-lacking motor neurons in TDP CKO mice showed that neuronal atrophy was evident at 100 weeks (Fig. 2F). In addition, we measured TDP-43 knockout efficiency in the small ( $>250 \mu\text{m}^2$ ) and large ( $<250 \mu\text{m}^2$ ) lumbar motor neurons. The results showed that there was no difference in the knockout efficiency between the small and large motor neurons (Supplementary Fig. 6A), suggesting that the TDP-43-knockout efficiency in the gamma-motor neurons of TDP CKO mice is similar to that of alpha-motor neurons. The measurement of the average motor neuron number showed that the number of TDP-43-lacking large motor neurons decreased at 100 weeks of age compared with TDP-43-positive motor neurons, whereas the number of TDP-lacking small motor neurons increased, indicating that postnatal deletion of TDP-43 leads to atrophy of the alpha-motor neurons in the aged TDP CKO mice (Supplementary Fig. 6B). This view is supported



**Figure 2** Morphological analysis of spinal motor neurons. (A and B) Immunofluorescent stainings (TDP-43, green; ChAT, red) of lumbar ventral horn from 100-week-old control (Ctl) and TDP CKO mice. (B) Enlarged image of the area marked in A (left). TDP-43-lacking motor neurons (arrows) were significantly smaller than TDP-43-positive motor neurons. (C) Percentage of TDP-43-positive motor neurons in the lumbar ventral horn of 100-week-old mice ( $n = 5$  for each group). (D) Average size of spinal motor neurons (MN) in 100-week-old mice ( $n = 5$  for each group). Error bars indicate SD. (E) Average number of spinal motor neurons in 100-week-old mice ( $n = 5$  for each group). Error bars indicate SD. (F) Time course of atrophy of TDP-43-lacking motor neurons ( $n = 5$  for each age). TDP+ = TDP-43-positive neurons; TDP- = TDP-43-negative neurons. Scale bars = 100  $\mu\text{m}$ .

by the immunofluorescent analysis of the lumbar ventral horn from 100-week-old TDP CKO mice showing that the TDP-43-lacking alpha-motor neuron, which was positive for NeuN and ChAT, was smaller than the TDP-43-positive alpha-motor neuron (Supplementary Fig. 6C). On the other hand, there was no morphological difference in the motor neurons between TDP hCKO and TDP-43<sup>flox/+</sup> mice (Supplementary Fig. 5E).

## TDP-43 depletion affects motor axon, neuromuscular junction and skeletal muscle

The toluidine blue staining of transverse sections of L5 ventral root exhibited axonal degeneration in a subset of large myelinated fibres of TDP CKO mice from 50 weeks (Fig. 3A). Quantitative analyses of the ventral roots demonstrated the decrease of large myelinated fibres and increase of small myelinated fibres in 100 week-old TDP CKO mice (Fig. 3A). The immunofluorescent analysis using anti-ChAT antibody also exhibited the loss of large motor axons in the ventral root of TDP CKO mice (Fig. 3B). Axial sections of the gastrocnemius muscle in 100-week-old TDP CKO mice exhibited grouped atrophy, a neurogenic muscular change (Fig. 3C). Whereas all assessed neuromuscular junctions in the control littermates were innervated, in the TDP CKO mice, the percentage of denervated neuromuscular junctions increased progressively after the age of 50 weeks, concomitant with motor impairment and motor neuron atrophy (Fig. 3D). In analyses of retrograde FluoroGold labelling of the motor neurons in TDP CKO mice, the degree of labelling was significantly less in the TDP-43-lacking motor neurons than in the TDP-43-positive motor neurons (Fig. 3E).

## Assessment in motor nuclei of cranial nerves

The histopathology of patients with ALS is characterized by the selective loss of motor neurons with scarcely detectable damage in the extraocular motor nuclei. To examine the region-specific neuropathology in TDP CKO mice, we quantitatively analysed the motor nuclei of cranial nerves. In the trigeminal motor, facial, hypoglossal and abductor nuclei of 100-week-old TDP CKO mice, ~50% of motor neurons were negative for TDP-43, but in the oculomotor nucleus, the efficiency of TDP-43 depletion was only ~25% (Supplementary Fig. 7). Morphological analysis of the trigeminal motor, facial and hypoglossal nuclei in 100-week-old TDP CKO mice revealed that TDP-43-lacking motor neurons were significantly smaller than those with TDP-43 or those of the control littermates (Fig. 4A–C), whereas those in the oculomotor and the abductor nuclei were preserved (Fig. 4D and E), suggesting that this mouse model recapitulates the selective vulnerability of motor neuron in ALS. The time course analysis of the hypoglossal motor nucleus showed that the atrophy of the motor neuron was evident from 50 weeks. The number of motor neurons in these nuclei of TDP CKO mice was not altered compared with the control littermates, as was shown in the spinal cord (Fig. 4A–E).

## Astrogliosis in ventral horn and accumulation of phosphorylated neurofilament in motor neurons of TDP CKO mice


Immunohistochemistry of the ventral horn showed that the number of astrocytes progressively increased in TDP CKO mice (Fig. 5A). Phosphorylated neurofilament accumulated in the cytoplasm of TDP-43-lacking motor neurons of TDP CKO mice, but not in motor neurons with TDP-43 in TDP CKO mice or those of control littermates (Fig. 5B).

## Formation of autophagosomes in motor neurons of TDP CKO mice

Recent studies indicate that autophagosomes accumulate in motor neurons of patients with sporadic ALS and animal models of motor neuron diseases (Li *et al.*, 2008; Sasaki, 2011; Tian *et al.*, 2011). Therefore, we investigated autophagy-related pathology in 100-week-old control and TDP CKO mice. The immunofluorescent analysis showed LC3-positive puncta in 37% of TDP-43-lacking motor neurons, but not in TDP-43-positive motor neurons in TDP CKO mice or those of the control littermates (Fig. 6A). TDP-43-lacking motor neurons with the puncta were significantly smaller than those without the puncta (Fig. 6B). The ultrastructure of motor neurons from 100-week-old TDP CKO mice demonstrated that autophagy-related structures such as autolysosomes and autophagosomes were accumulated in the cell bodies of motor neurons (Fig. 6C–E), proximal motor axon (Fig. 6F), and sciatic nerve of TDP CKO mice (Fig. 6G–H). These structures were not seen in the control mice as far as we observed.

## Discussion

Although TDP-43 is an established pathological hallmark of ALS, it remains unclear how TDP-43 contributes to the pathogenesis. In the present study, we showed that TDP CKO mice, in which TDP-43 was knocked-out specifically in postnatal motor neurons, developed an age-dependent progressive motor impairment such as gait disturbance and muscle atrophy, suggesting that the loss-of-function of TDP-43 in postnatal motor neurons plays a causative role in the neurodegenerative process of ALS. There has been a great deal of debate about whether loss or gain of TDP-43 function causes the neurodegeneration (Lee *et al.*, 2011). Several mouse, rat and primate models overexpressing wild-type or disease mutant TDP-43 recapitulate the phenotype of ALS or FTL (Wegorzewska *et al.*, 2009; Shan *et al.*, 2010; Stallings *et al.*, 2010; Tsai *et al.*, 2010; Wils *et al.*, 2010; Xu *et al.*, 2010; Zhou *et al.*, 2010; Igaz *et al.*, 2011; Swarup *et al.*, 2011; Uchida *et al.*, 2012); however, redistributions and cytoplasmic inclusions of TDP-43 are generally rare and several models exhibit cytoplasmic mitochondrial aggregation, which is not common in ALS. The expression of endogenous TDP-43 is suppressed in neurons expressing human TDP-43-delta nuclear localization signal as well as those expressing human wild-type TDP-43, suggesting that




**Figure 3** Analysis of motor axons, neuromuscular junctions, and skeletal muscles. (A) Toluidine blue staining images and the number of small myelinated fibres (<5 µm) and large myelinated fibres (>5 µm) in the L5 ventral root from 20, 50 and 100-week-old control and TDP CKO mice (n = 6 axons of each). The enlarged image of the yellow-framed area is also shown. Arrows indicate axonal degenerations. Scale bars = 100 µm. Error bars indicate SD. (B) Immunofluorescent staining of the L4 ventral root in 100-week-old mice with an anti-ChAT antibody. (C) Haematoxylin and eosin staining of gastrocnemius muscles of 100-week-old mice. Axial sections from TDP CKO mice exhibited grouped atrophy (arrow), whereas the control littermates showed no such phenomenon. (D) Immunofluorescent staining [synaptophysin (SYN) and phospho-neurofilament (NF), green; bungarotoxin (BTX), red] of neuromuscular junctions (NMJ) in 100-week-old mice and a time course analysis of neuromuscular junctions in TDP CKO mice. Denervated neuromuscular junctions (arrow) are indicated by the lack of synaptophysin and phospho-neurofilament staining. Scale bars = 50 µm. Error bars indicate SD (n = 3). (E) FluoroGold labelling (blue) and immunofluorescence staining (TDP-43, green; ChAT, red) of lumbar motor neurons. Retrograde FluoroGold labelling was significantly attenuated in TDP-43-lacking motor neurons but not in TDP-43-positive neurons in 100-week-old TDP CKO mice (arrows). Scale bars = 20 µm. Error bars indicate SD (n = 10).

mutant TDP-43 may cause neurodegeneration through inhibition of normal TDP-43 function (Igaz *et al.*, 2011). On the other hand, TDP-43 knockout mice result in embryonic lethal phenotypes (Kraemer *et al.*, 2010; Sephton *et al.*, 2010; Wu *et al.*, 2010),

and systemic postnatal deletion of this molecule led to rapid death (Chiang *et al.*, 2010). Although TDP-43-depleted models of *Drosophila* and zebrafish exhibit neurodevelopmental deficits in motor axons (Feiguin *et al.*, 2009; Kabashi *et al.*, 2011), the






**Figure 4** Morphological analysis of cranial motor nuclei. (A–E) Immunofluorescent analysis (TDP-43, green; ChAT, red) of motor neurons in the trigeminal motor (m.) (A), facial (B), hypoglossal (C), oculomotor (D), and abductor (E) nuclei from 100-week-old control ( $n = 3$ ) and TDP CKO mice ( $n = 3$ ). Graphs show the average size and number of motor neurons in each area. TDP+ = TDP-43-positive neuron; TDP– = TDP-43-negative neuron. Error bars indicate SD. Scale bars = 50 μm. MN = motor neuron; N.S. = not significant.

role of TDP-43 in postnatal mammalian neurons has not been fully elucidated. In the present study, we clarified that TDP CKO mice, in which TDP-43 was specifically knocked-out by Cre recombinase in postnatal motor neurons, develops a progressive motor neuronal degeneration as seen in ALS, suggesting that TDP-43 is essential for the long term maintenance of postnatal motor neurons in mice. Although TDP CKO mice developed ALS-like motor impairment, the mortality of the mice was not different from that of control littermates. This might be due to the knockout efficiency of TDP-43, which occurred in ~50% of motor neurons, or due to the life span of mice, which is considerably shorter than the disease duration of patients with ALS. Moreover, there were no

significant alterations in body weight, motor function or morphology of motor neurons in our TDP heterozygous CKO (TDP hCKO) mice. Because previous studies demonstrated that the protein expression of TDP-43 was not reduced in various tissues of heterozygous TDP-43 knockout mice (Kraemer *et al.*, 2010; Sephton *et al.*, 2010; Wu *et al.*, 2010), TDP-43 depletion is likely insufficient to affect the motor neurons in our TDP hCKO mice. At the same time, these data suggest that expression of Cre itself did not affect the vulnerability of the mouse motor neurons over 2 years.

An earlier study demonstrates that the motor neuron-specific TDP-43 knockout mouse carrying HB9-Cre exhibits early-onset




**Figure 5** Astroglisis and neuronal accumulation of phosphorylated neurofilament. (A) Immunohistochemistry against GFAP in the ventral horn and a time course analysis of astroglisis. Error bars indicate SD ( $n = 3$  for each age). (B) Immunofluorescent staining against pNF-H (green), ChAT (red) and TDP-43 (blue). pNF-H was accumulated in the cell bodies of TDP-43-lacking motor neurons of TDP CKO mice (arrows). Scale bars: A = 100  $\mu$ m; B = 50  $\mu$ m.

motor dysfunction and develops motor neuronal loss earlier than 10 weeks of age (Wu *et al.*, 2012). However, given that the Cre-mediated recombination using the *HB9* promoter began at the developmental stage E9.5 (Arber *et al.*, 1999), this model possibly reflects the loss-of-function of TDP-43 in the motor neuron development. By contrast, because the Cre expression in VAcHt-Cre.Fast mice is mediated by the VAcHt promoter, the number of Cre-expressing motor neurons in VAcHt-Cre.Fast mice is scarcely detected at prenatal stages, but becomes maximum in number at 5 weeks (Misawa *et al.*, 2003). We also confirmed that TDP-43 was not excised in spinal motor neurons of TDP CKO mice at post-natal Day 2, but knocked-out in ~50 % of motor neurons of the 10-week-old mice. This temporal pattern of Cre expression appears to contribute to the late-onset progressive motor dysfunction in our TDP CKO mice and enable the assessment of loss of TDP-43 functions in mouse motor neurons at the postnatal stage. As far as we investigated, TDP-43 was knocked-out in spinal motor neurons beginning at 10 weeks, but the function and morphology of motor neurons were unexpectedly preserved for 1 year in TDP CKO mice, suggesting that the loss of TDP-43 was compensated in motor neurons of young

mice, but triggered neuronal vulnerability with the ageing process. Given that ALS is an age-related neurodegenerative disease and that the disease develops after middle age even in inherited cases with TDP-43 mutations (Gitcho *et al.*, 2008; Kabashi *et al.*, 2008; Sreedharan *et al.*, 2008; Yokoseki *et al.*, 2008), our TDP CKO mice appear to be a model that recapitulates the age-dependent phenotypes of ALS. However, as TDP CKO mice lack some aspects of human ALS pathology, such as cytoplasmic inclusions of TDP-43 and the involvement of upper motor neurons, the use of this model for therapeutic research needs further validation.

In the histopathological analyses, TDP CKO mice exhibited the atrophy of motor neurons, degeneration of large motor axons, denervation of neuromuscular junctions and grouped atrophy of skeletal muscles, all of which are common to the pathology of human motor neuron disease. The disruption of retrograde labelling in TDP-43-lacking motor neurons suggests that TDP-43 depletion directly induces neuronal dysfunction. Interestingly, the axonal degenerations were evident in the ventral root of TDP CKO mice at 50 weeks of age, when the morphology of lumbar motor neurons was not altered. These findings are compatible with the fact that ALS pathology initially manifests at the axon



**Figure 6** Formation of autophagosomes in motor neurons of TDP CKO mice. (A) Immunofluorescent analysis (LC3, green; ChAT, red; TDP-43, blue) revealed LC3-positive cytoplasmic puncta in TDP-43-lacking motor neurons of 100-week-old TDP CKO mice. (B) The average size of TDP-43 lacking motor neurons (MN) with ( $n = 25$ ) and without ( $n = 48$ ) LC3-positive puncta. Error bars indicate SEM. (C–I) Ultrastructural analysis of 100-week-old TDP CKO mice. Autophagosomes (arrows) and an autolysosome (double arrows) (C), autolysosomes surrounded by a single membrane containing mitochondria (D) and autophagosomes containing ribosome-like structures (E) were observed in the cell bodies of the motor neurons. An autophagic structure in the proximal motor axon (F). Accumulation of organelles containing mitochondria, autophagosomes (arrows), autolysosomes (double arrows), and autophagic structure with a multi-lamellelated structure (arrowhead) in the sciatic nerve (G) and its enlarged images (D, E, H and I). Scale bars: A = 20 μm; C and G = 1 μm; F, H and I = 500 nm.

(Fischer *et al.*, 2004). The increase of small myelinated fibres accompanied by the decrease of large myelinated fibres in the ventral root of 100-week-old TDP CKO mice corresponds to the morphological change in the cell body of the motor neurons, and similar observations were also reported in the patients and mouse models of ALS (Bradley *et al.*, 1983; Zhang *et al.*, 1997). TDP CKO mice also exhibited several features that are shared with patients with sporadic ALS: the involvement in the cranial motor nuclei such as the hypoglossal nucleus, preserved morphology in the extraocular motor neurons, accumulations of phosphorylated neurofilament in motor neurons and astrogliosis in the spinal ventral horn. Dysphagia due to the involvement of the hypoglossal nucleus might enhance the weight loss in aged TDP CKO mice through decreased oral intake. In ALS, extraocular motor neurons are resistant to degeneration compared with other somatomotor neurons, and differences in calcium buffering capacities have been proposed as a possible reason for this selective vulnerability (Alexianu *et al.*, 1994; Reiner *et al.*, 1995; Laslo *et al.*, 2000). Because RNA-seq analysis demonstrates that depletion of

TDP-43 affects the calcium signalling pathway in mouse striatum (Polymenidou *et al.*, 2011), it is possible that dysregulation of calcium buffering underlies the pathogenesis of TDP CKO mice.

Our immunofluorescent analysis also demonstrated LC3-positive cytoplasmic puncta in TDP-43-depleted motor neurons, and the presence of these puncta was associated with shrinkage of motor neurons. This finding was confirmed by electron microscopy that revealed the presence of autolysosomes and autophagosomes in the motor neuronal cell bodies and axons of TDP CKO mice, suggesting that TDP-43 depletion resulted in dysregulation of the autophagic pathway. In addition, the accumulation of autophagic structures in the sciatic nerve and the disruption of retrograde labelling in TDP-43-lacking motor neurons suggest that the disruption of retrograde axonal transport may underlie the motor neuronal dysfunction in TDP CKO mice. Although the disruption of constitutive autophagy is shown to instigate the degeneration of certain types of neurons (Komatsu *et al.*, 2006), the causative role of the autophagic dysregulation in the pathogenesis of motor neuron diseases remains controversial. A recent work

demonstrates that motor neuron-specific knockout of the proteasome subunit Rpt3, but not autophagy mediator Atg7, leads to motor neuron degeneration in mice (Tashiro *et al.*, 2012), suggesting that the disruption of autophagic pathway in motor neurons may not be the primary cause of the neurodegeneration. However, accumulation of autophagosomes and autolysosomes was observed in the motor neurons of mice with mutant SOD1 (Li *et al.*, 2008; Tian *et al.*, 2011) and patients with sporadic ALS (Nakano *et al.*, 1993; Sasaki, 2011). In addition, mice carrying mutations of dynein or dynactin exhibit motor dysfunction with accumulation of autophagosomes in the motor neurons (Ravikumar *et al.*, 2005; Laird *et al.*, 2008). These lines of evidence may suggest a possible link between the increased autophagosomes and the process of motor neuron degeneration (Pasquali *et al.*, 2009; Chen *et al.*, 2012), although it remains unclear whether the accumulation of autophagosomes in neurodegenerative diseases results from activation of autophagy, disruption of retrograde transport or decreased lysosome fusion (Shintani and Klionsky, 2004; Baehrecke, 2005; Perlson *et al.*, 2010). Further investigation with regard to the linkage among loss of TDP-43, retrograde axonal transport and dysregulation of autophagy might contribute to our understanding the pathogenesis of ALS.

In conclusion, TDP CKO mice exhibited age-dependent motor impairment and morphological alterations in the motor neuron system that recapitulate several features of sporadic ALS neuropathology, including the accumulation of autophagosomes. These findings suggest that TDP-43 plays an essential role in the long-term maintenance of motor neurons, and that loss of TDP-43 function contributes to the pathogenesis of ALS.

## Funding

This work was supported by a Centre of Excellence (COE) grant, a Grant in Aid for Scientific Research on Innovated Areas 'Foundation of Synapse and Neurocircuit Pathology', and Grants in-Aid from Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan; grants from the Ministry of Health, Labour and Welfare of Japan; and Core Research for Evolutional Science and Technology (CREST) of the Japan Science and Technology Agency (JST); Strategic Research Program for Brain Sciences of the MEXT of Japan.

## Supplementary material

Supplementary material is available at *Brain* online.

## References

- Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG, Appel SH. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. *Ann Neurol* 1994; 36: 846–58.
- Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem Biophys Res Commun* 2006; 351: 602–11.
- Arber S, Han B, Mendelsohn M, Smith M, Jessell TM, Sockanathan S. Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. *Neuron* 1999; 23: 659–74.
- Ayala YM, Misteli T, Baralle FE. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. *Proc Natl Acad Sci USA* 2008; 105: 3785–9.
- Ayala YM, Pantano S, D'Ambrogio A, Buratti E, Brindisi A, Marchetti C, et al. Human, *Drosophila*, and *C.elegans* TDP43: nucleic acid binding properties and splicing regulatory function. *J Mol Biol* 2005; 348: 575–88.
- Baehrecke EH. Autophagy: dual roles in life and death? *Nat Rev Mol Cell Biol* 2005; 6: 505–10.
- Bradley WG, Good P, Rasool CG, Adelman LS. Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis. *Ann Neurol* 1983; 14: 267–77.
- Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. *J Biol Chem* 2005; 280: 37572–84.
- Buratti E, De Conti L, Stuani C, Romano M, Baralle M, Baralle F. Nuclear factor TDP-43 can affect selected microRNA levels. *FEBS J* 2010; 277: 2268–81.
- Chen S, Zhang X, Song L, Le W. Autophagy dysregulation in amyotrophic lateral sclerosis. *Brain Pathol* 2012; 22: 110–6.
- Chiang PM, Ling J, Jeong YH, Price DL, Aja SM, Wong PC. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. *Proc Natl Acad Sci USA* 2010; 107: 16320–4.
- Feiguin F, Godena VK, Romano G, D'Ambrogio A, Klima R, Baralle FE. Depletion of TDP-43 affects *Drosophila* motoneurons terminal synapses and locomotive behavior. *FEBS Lett* 2009; 583: 1586–92.
- Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. *Exp Neurol* 2004; 185: 232–40.
- Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, et al. TDP-43 A315T mutation in familial motor neuron disease. *Ann Neurol* 2008; 63: 535–8.
- Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. *J Clin Invest* 2011; 121: 726–38.
- Iguchi Y, Katsuno M, Niwa J, Yamada S, Sone J, Waza M, et al. TDP-43 depletion induces neuronal cell damage through dysregulation of Rho family GTPases. *J Biol Chem* 2009; 284: 22059–66.
- Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourguoin P, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits *in vivo*. *Hum Mol Genet* 2011; 19: 671–83.
- Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat Genet* 2008; 40: 572–4.
- Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. *Neuron* 2002; 35: 843–54.
- Katsuno M, Adachi H, Minamiyama M, Waza M, Tokui K, Banno H, et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. *J Neurosci* 2006; 26: 12106–17.
- Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* 2006; 441: 880–4.
- Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. *Acta Neuropathol* 2010; 119: 409–19.
- Laird FM, Farah MH, Ackerley S, Hoke A, Maragakis N, Rothstein JD, et al. Motor neuron disease occurring in a mutant dynactin mouse